Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEGylated haemoglobin and carbon monoxide - Prolong Pharmaceuticals

Drug Profile

PEGylated haemoglobin and carbon monoxide - Prolong Pharmaceuticals

Alternative Names: PEG haemoglobin; PEG haemoglobin carbon monoxide; PEG-bHb-CO; PEG-COHb; PEG-haemoglobin-CO; PEG-Hb; PEG-LEH; Pegylated carboxyhemoglobin bovine; Pegylated haemoglobin carbon monoxide; Polyethylene glycol modified bovine haemoglobin; Sanguinate

Latest Information Update: 05 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enzon Pharmaceuticals; Rutgers
  • Developer Prolong Pharmaceuticals
  • Class Haemoglobins; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Delayed graft function
  • Phase II Cerebral ischaemia; Leg ulcer; Vaso-occlusive crisis
  • Clinical Phase Unknown Beta-thalassaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 May 2018 Prolong Pharmaceuticals withdraws a phase II trial for Delayed graft function in Brazil prior to enrolment (NCT02658162)
  • 03 Jan 2018 Phase I development in Vaso-occlusive crisis related to sickle cell anaemia is ongoing (Prolong Pharmaceuticals pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top